Cargando…

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

BACKGROUND: Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express nuclear androgen receptor (AR) and androgen regulated genes. We recently reported that C-terminal truncated constitutively active AR splice variants contribute to CRPC development. Si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaotun, Morrissey, Colm, Sun, Shihua, Ketchandji, Melanie, Nelson, Peter S., True, Lawrence D., Vakar-Lopez, Funda, Vessella, Robert L., Plymate, Stephen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219707/ https://www.ncbi.nlm.nih.gov/pubmed/22114732 http://dx.doi.org/10.1371/journal.pone.0027970

Ejemplares similares

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment
por: Bianchi-Frias, Daniella, et al.
Publicado: (2010)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
por: Nguyen, Holly M., et al.
Publicado: (2017)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
por: Morrissey, Colm, et al.
Publicado: (2007)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

Diagnosing 12 prostate needle cores within an hour of biopsy via open-top light-sheet microscopy
por: Xie, Weisi, et al.
Publicado: (2020)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
por: Brady, Lauren, et al.
Publicado: (2021)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
por: Hörnberg, Emma, et al.
Publicado: (2011)

Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures
por: Chattopadhyay, Indranil, et al.
Publicado: (2016)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
por: Schweizer, Michael T., et al.
Publicado: (2016)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012)

Molecular subtyping bladder cancer: Is it ready for clinical practice?
por: VAKAR LOPEZ, Funda
Publicado: (2020)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
por: Pritchard, Colin C., et al.
Publicado: (2014)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
por: Sawant, Mithila, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tarl6i7h9qvvpv28p41lboi9lv